Astellas Pharma, Inc. (ALPMF)
17.32
+0.77
(+4.65%)
USD |
OTCM |
Nov 13, 16:00
Astellas Pharma Net Income (Quarterly) : 626.57M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 626.57M |
| June 30, 2026 | 889.54M |
| March 31, 2026 | 278.00M |
| December 31, 2025 | 651.15M |
| September 30, 2025 | 537.30M |
| June 30, 2025 | 473.28M |
| March 31, 2025 | 491.43M |
| December 31, 2024 | -640.89M |
| September 30, 2024 | 240.61M |
| June 30, 2024 | 241.31M |
| March 31, 2024 | -224.13M |
| December 31, 2023 | 98.13M |
| September 30, 2023 | -10.09M |
| June 30, 2023 | 240.88M |
| March 31, 2023 | -348.39M |
| December 31, 2022 | 342.29M |
| September 30, 2022 | 517.77M |
| June 30, 2022 | 191.10M |
| March 31, 2022 | -72.30M |
| December 31, 2021 | 535.37M |
| September 30, 2021 | 371.73M |
| June 30, 2021 | 280.51M |
| March 31, 2021 | -116.19M |
| December 31, 2020 | 575.00M |
| September 30, 2020 | 211.28M |
| Date | Value |
|---|---|
| June 30, 2020 | 468.85M |
| March 31, 2020 | 49.46M |
| December 31, 2019 | 565.67M |
| September 30, 2019 | 652.23M |
| June 30, 2019 | 532.36M |
| March 31, 2019 | 278.99M |
| December 31, 2018 | 777.40M |
| September 30, 2018 | 442.32M |
| June 30, 2018 | 499.81M |
| March 31, 2018 | 203.74M |
| December 31, 2017 | 535.89M |
| September 30, 2017 | 357.32M |
| June 30, 2017 | 382.12M |
| March 31, 2017 | 351.36M |
| December 31, 2016 | 582.02M |
| September 30, 2016 | 473.36M |
| June 30, 2016 | 617.28M |
| March 31, 2016 | 253.02M |
| December 31, 2015 | 507.37M |
| September 30, 2015 | 477.29M |
| June 30, 2015 | 367.50M |
| March 31, 2015 | 177.16M |
| December 31, 2014 | 391.11M |
| September 30, 2014 | 328.19M |
| June 30, 2014 | 351.24M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Pfizer Inc. | 3.251B |
| Takeda Pharmaceutical Co., Ltd. | 1.209B |
| Daiichi Sankyo Co., Ltd. | 530.10M |
| Eisai Co., Ltd. | 76.10M |
| Chugai Pharmaceutical Co., Ltd. | 901.42M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 3.956B |
| Total Expenses (Quarterly) | 3.328B |
| EPS Diluted (Quarterly) | 0.3486 |
| Enterprise Value | 32.26B |
| Gross Profit Margin (Quarterly) | 74.48% |
| Profit Margin (Quarterly) | 15.84% |
| Earnings Yield | 7.86% |
| Operating Earnings Yield | 11.32% |
| Normalized Earnings Yield | 7.857 |